Skip to main content
Journal cover image

Vaccine Therapies for Cancer: Then and Now.

Publication ,  Journal Article
Morse, MA; Gwin, WR; Mitchell, DA
Published in: Target Oncol
March 2021

There are strong biologic and preclinical rationales for the development of therapeutic cancer vaccines; however, the clinical translation of this treatment strategy has been challenging. It is now understood that many previous clinical trials of cancer vaccines used target antigens or vaccine designs that inherently lacked sufficient immunogenicity to induce clinical responses. Despite the historical track record, breakthrough advances in cancer immunobiology and vaccine technologies have supported continued interest in therapeutic cancer vaccinations, with the hope that next-generation vaccine strategies will enable patients with cancer to develop long-lasting anti-tumor immunity. There has been substantial progress identifying antigens and vaccine vectors that lead to strong and broad T cell responses, tailoring vaccine designs to achieve optimal antigen presentation, and finding combination partners employing complementary mechanisms of action (e.g., checkpoint inhibitors) to overcome the diverse methods cancer cells use to evade and suppress the immune system. Results from randomized, phase 3 studies testing therapeutic cancer vaccines based on these advances are eagerly awaited. Here, we summarize the successes and failures in the clinical development of cancer vaccines, address how this historical experience and advances in science and technology have shaped efforts to improve vaccines, and offer a clinical perspective on the future role of vaccine therapies for cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Target Oncol

DOI

EISSN

1776-260X

Publication Date

March 2021

Volume

16

Issue

2

Start / End Page

121 / 152

Location

France

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Cancer Vaccines
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morse, M. A., Gwin, W. R., & Mitchell, D. A. (2021). Vaccine Therapies for Cancer: Then and Now. Target Oncol, 16(2), 121–152. https://doi.org/10.1007/s11523-020-00788-w
Morse, Michael A., William R. Gwin, and Duane A. Mitchell. “Vaccine Therapies for Cancer: Then and Now.Target Oncol 16, no. 2 (March 2021): 121–52. https://doi.org/10.1007/s11523-020-00788-w.
Morse MA, Gwin WR, Mitchell DA. Vaccine Therapies for Cancer: Then and Now. Target Oncol. 2021 Mar;16(2):121–52.
Morse, Michael A., et al. “Vaccine Therapies for Cancer: Then and Now.Target Oncol, vol. 16, no. 2, Mar. 2021, pp. 121–52. Pubmed, doi:10.1007/s11523-020-00788-w.
Morse MA, Gwin WR, Mitchell DA. Vaccine Therapies for Cancer: Then and Now. Target Oncol. 2021 Mar;16(2):121–152.
Journal cover image

Published In

Target Oncol

DOI

EISSN

1776-260X

Publication Date

March 2021

Volume

16

Issue

2

Start / End Page

121 / 152

Location

France

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Cancer Vaccines
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis